{"filings":[{"id":2026478,"accession_number":"0001193125-26-330804","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2026-08-03T21:06:22+00:00","items":["8.01","9.01"],"status":"ready","headline":"Stoke Therapeutics files prospectus supplement for up to $200M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on Aug 3, 2026 to sell up to $200M of common stock.","Shares offered under existing Controlled Equity Offering Sales Agreement with Cantor Fitzgerald.","Prospectus supplement part of automatic shelf registration statement filed March 18, 2026.","Legal opinion of Fenwick & West LLP filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2024200,"accession_number":"0001193125-26-330537","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2026-08-03T20:05:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stoke Therapeutics Q2 net loss $61.6M; Phase 3 EMPEROR enrollment complete at 162 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $61.6M ($0.93 per share) vs $23.5M loss in Q2 2025; revenue fell to $9.3M from $13.8M.","Cash, equivalents and marketable securities $420M (incl. $65.7M post-quarter ATM sale); funds operations to potential 2028 launch.","Phase 3 EMPEROR study of zorevunersen enrolled 162 patients; data readout expected Q3 2027.","Pre-NDA meeting with FDA scheduled H2 2026; rolling NDA submission to begin Q1 2027.","Phase 1 OSPREY study of STK-002 for ADOA: sentinel cohort dosed, initial data anticipated H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1342879,"accession_number":"0001193125-26-289409","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2026-06-30T12:02:16+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Stoke completes enrollment of 162 patients in Phase 3 EMPEROR study of zorevunersen for Dravet syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed enrollment of 162 patients in Phase 3 EMPEROR study of zorevunersen for Dravet syndrome.","Plans to initiate rolling NDA submission to FDA in Q1 2027; data readout anticipated in Q3 2027.","Approximately 50 of 162 patients have passed 28-week primary endpoint measurement; no discontinuations.","Additional cohort of ~30 patients enrolling in Europe; last patient expected in August.","Potential FDA approval and U.S. launch by early 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":860996,"accession_number":"0001193125-26-257394","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2026-06-04T20:08:29+00:00","items":["5.07"],"status":"ready","headline":"Stoke Therapeutics stockholders elect three Class I directors at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected G. Clare Kahn, Ph.D. (49,722,339 for), Adrian Krainer, Ph.D. (36,531,612 for), and Julie Anne Smith (43,500,649 for) as Class I directors.","Ratified Ernst & Young LLP as independent auditor for FY 2026 with 55,121,163 votes for, 2,036 against.","Advisory vote on named executive officer compensation passed: 36,436,275 for, 13,565,293 against, 29,415 abstaining."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94150,"accession_number":"0001193125-26-212020","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stoke reports Q1 net loss $50M; new 4-year OLE data supports zorevunersen disease-modifying potential","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $50.0M ($0.79/share) vs prior-year net income $112.9M; revenue $6.2M down from $158.6M due to 2025 Biogen license revenue.","Cash $411M funded into 2028; includes $80.7M from ATM sales of 2.6M shares in Q1.","New 4-year OLE data: durable seizure reductions, statistically significant cognition/behavior gains at 1-4 years; generally well tolerated.","Phase 3 EMPEROR enrollment (~150 pts) expected to complete June 2026, data readout mid-2027; NDA submission planned Q1 2027.","First patient dosed in Phase 1 OSPREY (STK-002 for ADOA); SYNGAP1 candidate selection targeted in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":6229000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94149,"accession_number":"0001193125-26-145524","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Stoke Therapeutics appoints Clare Kahn, Ph.D. to Board, increases size to ten","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 10 directors; Kahn appointed as Class I director effective April 3, 2026.","Kahn receives $45k annual cash retainer and initial option for 30,782 shares (~$724k grant-date value).","Kahn will chair the R&D Committee and serve on the Nominating & Corporate Governance Committee.","Kahn brings 30+ years drug development and regulatory experience from X-VAX, Pfizer, and GSK.","Company is advancing Phase 3 study of zorevunersen for Dravet syndrome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106320,"accession_number":"0001193125-26-129168","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Stoke Therapeutics dismisses KPMG, appoints Ernst & Young as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On March 23, 2026, Audit Committee dismissed KPMG as independent registered public accounting firm.","KPMG's reports for FY2024 and FY2025 contained no adverse opinion, disclaimer, or qualification.","No disagreements or reportable events occurred during fiscal years 2024-2025 or interim period through March 23, 2026.","Audit Committee approved engagement of Ernst & Young LLP as independent auditor for FY ending December 31, 2026.","Company had no prior consultations with EY regarding accounting matters described in Item 304(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106319,"accession_number":"0001193125-26-088205","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Stoke Therapeutics awards CEO Ian F. Smith $697K discretionary bonus for 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discretionary bonus of $697,125 for CEO Ian F. Smith, equal to full target bonus for 2025.","Smith did not participate in 2025 annual bonus program; Board determined corporate goal achievement at 150% of target.","Bonus based on clinical and financial performance since Smith's appointment as interim CEO in March 2025 and permanent CEO in Oct 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106318,"accession_number":"0001193125-26-022569","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Stoke Therapeutics enters $85.5M lease for 98,500 sq ft Waltham HQ/lab through 2038","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New lease with NWALP PHOP Property Owner LLC for 98,500 sq ft at 245 Fifth Avenue, Waltham, MA.","Aggregate base rent ~$85.5M over term ending March 31, 2038; two five-year extension options at market rate.","Security deposit of $3M in form of irrevocable standby letter of credit, reducible over time.","Lease supports expansion of corporate headquarters and laboratory space."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106317,"accession_number":"0001193125-26-009781","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Stoke Therapeutics accelerates EMPEROR enrollment, expects Phase 3 data in mid-2027, cash $391.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment of 150 patients in Phase 3 EMPEROR study expected to complete in Q2 2026, accelerated from prior timeline.","Phase 3 data readout planned for mid-2027; rolling NDA submission to initiate in first half 2027.","FDA multidisciplinary meeting held; no immediate program changes, but discussions ongoing for expedited pathways.","Cash, equivalents and marketable securities $391.7M as of Dec 31, 2025; plus Biogen proceeds funds operations into 2028.","Nearly 330 potential study candidates identified globally; ~60 in screening, ~60 randomized/dosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122640,"accession_number":"0001193125-25-308781","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Stoke and Biogen present data supporting zorevunersen's disease-modifying potential for Dravet syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Propensity score weighted analysis shows statistically significant reductions in major motor seizure frequency at 6 months (70mg loading dose) vs natural history.","Improvements in cognition and behavior (Vineland-3) at 18 months with 45mg dosing; durable effects through 24 months.","EEG analysis reveals dose-dependent decrease in abnormal brain activity; reduction in EEG abnormality correlated with seizure reduction.","Safety: 81 patients, >800 doses; CSF protein elevations in 42% (Phase 1/2a) and 86% (OLE) but no clinical manifestations; 3 unrelated deaths (2 SUDEP, 1 malnutrition).","Data are consistent with endpoints in ongoing Phase 3 EMPEROR study (week 28 primary, 18-month secondary)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122639,"accession_number":"0001193125-25-264644","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stoke Q3 net loss $38.3M ($0.65/sh); Phase 3 EMPEROR >20 randomized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.3M ($0.65/sh) vs $26.4M ($0.47) in Q3 2024; revenue $10.6M vs $4.9M.","Cash $328.6M as of Sep 30; $48.7M from Oct share sales; funded to mid-2028.","Phase 3 EMPEROR: >20 patients randomized, ~35 in screening; enrollment on track for H2 2026.","FDA meeting planned before year-end to discuss expedited regulatory pathways for zorevunersen.","Ian F. Smith appointed permanent CEO (was interim); Arthur Tzianabos resumes Chairman role."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":183018000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122638,"accession_number":"0001193125-25-230925","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Stoke Therapeutics appoints Ian F. Smith as permanent CEO; interim role since March 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian F. Smith, 59, appointed CEO effective Oct 6, 2025; served as interim CEO since March 19, 2025.","Annual base salary of $715,000; eligible for annual bonus target of 65% of base salary (no 2025 bonus).","Receives $500,000 sign-on bonus (repayable if resigns within 12 months) and $500,000 performance bonus based on metrics.","Equity grant: option for 570,000 shares (4-yr vest) and RSU for 380,000 shares (4-yr annual vest).","Dr. Tzianabos resigns as Interim Executive Chair, resumes as independent director and Chair of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139338,"accession_number":"0001193125-25-207401","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K/A","filed_at":"2025-09-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stoke Therapeutics to hold annual Say-on-Pay votes through 2031 based on stockholder vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted in favor of one-year frequency for advisory Say-on-Pay votes at June 3 annual meeting.","Board had recommended annual Say-on-Pay votes in its proxy statement.","Company will hold annual Say-on-Pay votes until the next required frequency vote, no later than 2031.","This 8-K/A amends the original 8-K filed June 4, 2025, solely to disclose the frequency decision.","No other changes were made to the original 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139341,"accession_number":"0000950170-25-107275","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Stoke Q2 net loss $23.5M; Phase 3 EMPEROR dosed, 3-year OLE data show durability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.5M ($0.40/sh) for Q2 2025 vs $25.7M loss in Q2 2024; H1 net income $89.4M from Biogen collaboration.","First patient dosed in global Phase 3 EMPEROR study of zorevunersen for Dravet syndrome; sites active in US, UK, Japan.","New 3-year OLE data show durable seizure reductions and continued improvements in cognition/behavior.","Phase 1 OSPREY study of STK-002 initiated for Autosomal Dominant Optic Atrophy (ADOA).","Cash $355M as of June 30, 2025, expected to fund operations to mid-2028 and into launch readiness."],"consensus_eps_estimate":null,"consensus_eps_actual":1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":172386000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139340,"accession_number":"0001193125-25-177433","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"First patient dosed in Phase 3 EMPEROR study of zorevunersen for Dravet syndrome by Stoke and Biogen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in global Phase 3 EMPEROR study of zorevunersen for Dravet syndrome.","Randomized 1:1 vs sham over 52 weeks; primary endpoint: change in major motor seizure frequency at Week 28.","Zorevunersen is an investigational antisense oligonucleotide; potential first disease-modifying treatment for Dravet syndrome.","Key secondary endpoints include cognition/behavior via Vineland-3 subdomains at Week 52.","Enrollment: ages 2-18 with SCN1A mutation; open-label extension offered to eligible participants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139339,"accession_number":"0001193125-25-157364","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Stoke/Biogen present zorevunersen Phase 3 EMPEROR analysis showing cognition/behavior improvements at Week 68","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Analysis of patients on EMPEROR-like regimen (2x70mg loading + 2x45mg maintenance) showed cognition/behavior improvements at Week 68.","Results contrast with natural history (BUTTERFLY) where standard-of-care patients did not show improvements.","Five Vineland-3 sub-domains (Receptive/Expressive Communication, Interpersonal Relationships, Coping/Personal Skills) added as key secondary endpoints in Phase 3 EMPEROR.","Data complement prior Phase 1/2a and OLE results showing durable seizure reductions and improvements through two years.","Zorevunersen is a first-in-class potential disease-modifying RNA medicine for Dravet syndrome co-developed with Biogen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156919,"accession_number":"0001193125-25-134882","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stoke Therapeutics shareholders elect three Class III directors at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Edward M. Kaye, Seth L. Harrison, and Arthur O. Tzianabos elected as Class III directors with ~29.2M votes each.","Ratification of KPMG as independent auditor for FY2025 approved with 38.7M for vs 67.8K against.","Non-binding advisory vote on named executive officer compensation approved with 30.5M for vs 2.9M against.","Advisory vote on frequency of future say-on-pay set at one year (33.1M votes) as preferred frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156918,"accession_number":"0001193125-25-134447","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Stoke Therapeutics initiates Phase 3 EMPEROR study of zorevunersen; first US sites in May 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated Phase 3 EMPEROR study of zorevunersen; first U.S. sites activated in May 2025.","Updated corporate presentation posted to website on June 4, 2025, for Jefferies Global Healthcare Conference.","No other material financial or operational updates disclosed beyond the study initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156917,"accession_number":"0000950170-25-069783","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stoke Therapeutics Q1 2025 net income $112.9M; advances zorevunersen Phase 3 with Biogen","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $112.9M ($1.90 diluted EPS) in Q1 2025 vs net loss $26.4M ($0.57 per share) in Q1 2024.","Revenue $158.5M, including $152.4M from Biogen license fee and $6.1M from Acadia partnership.","Cash position $380.3M as of Mar 31, 2025; projected to fund operations beyond mid-2028.","Phase 3 EMPEROR study of zorevunersen for Dravet syndrome cleared with FDA, EMA, PMDA; enrollment in Q2 2025.","Biogen collaboration: $165M upfront, potential $385M milestones, tiered royalties; Stoke retains North America rights."],"consensus_eps_estimate":null,"consensus_eps_actual":1.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":158569000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175298,"accession_number":"0000950170-25-040758","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Stoke Therapeutics CEO Kaye steps down; Ian Smith named interim; FY 2024 net loss $89M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Edward Kaye steps down March 19; Ian F. Smith appointed Interim CEO; Arthur Tzianabos named Interim Executive Chair.","Full year 2024 net loss $89.0M ($1.65/share) vs $104.7M loss in 2023; revenue $36.6M from Acadia collaboration (vs $8.8M prior year).","Cash, equivalents, and marketable securities $246.7M at Dec 31, 2024; plus $165M upfront from Biogen collaboration funds operations to mid-2028.","Phase 3 registrational study (EMPEROR) of zorevunersen for Dravet syndrome on track to initiate in Q2 2025.","Board initiates search for permanent CEO; Kaye remains as advisor and director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175297,"accession_number":"0001193125-25-028650","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Stoke and Biogen enter $165M upfront collaboration for zorevunersen (Dravet syndrome)","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stoke receives $165M upfront; eligible for up to $385M in milestones and low-double-digit to high-teen royalties.","Stoke retains exclusive rights in US, Canada, Mexico; Biogen gets rest-of-world commercialization rights.","Phase 3 EMPEROR study to start Q2 2025 with pivotal data readout expected 2H 2027.","Cash runway extended to mid-2028, including upfront payment and other eligible cash flows.","Zorevunersen has FDA Breakthrough Therapy designation; Phase 1/2a showed substantial seizure reduction and cognitive improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175296,"accession_number":"0001193125-25-002550","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Stoke announces global regulatory alignment for Phase 3 study of zorevunersen in Dravet syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aligned with FDA, EMA, and PMDA for Phase 3 EMPEROR; study to start mid-2025, data by end of 2027.","Primary endpoint: reduction in major motor seizure frequency; key secondary: cognition and behavior via Vineland-3.","Dosing: two 70mg loading doses then two 45mg maintenance doses over 52 weeks; ages 2 to <18.","Commercial opportunity: >38,000 patients with Dravet syndrome in seven major markets.","FDA Breakthrough Therapy designation; prior OLE data: 87% median seizure reduction at month 8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192255,"accession_number":"0001193125-24-272559","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Stoke Therapeutics receives FDA Breakthrough Therapy Designation for zorevunersen in Dravet syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation for zorevunersen to treat Dravet syndrome with a confirmed SCN1A mutation.","Phase 1/2a data showed 85% median reduction in convulsive seizure frequency at 3 months post-last dose of 70mg.","OLE study patients on 45mg maintenance achieved 87% median reduction in seizures at month eight.","Patients showed continuous improvements in cognition and behavior through 2 years of treatment per Vineland-3.","Company plans to provide Phase 3 registrational study update by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192254,"accession_number":"0000950170-24-121068","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stoke Therapeutics Q3 net loss $26.4M; FDA lifts partial clinical hold on zorevunersen; STK-002 Phase 1 delayed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities $269.2M as of Sep 30, 2024.","Net loss Q3 2024 $26.4M ($0.47/shr) vs $24.5M ($0.55/shr) Q3 2023.","Revenue from Acadia collaboration $4.9M in Q3 2024 vs $3.3M in Q3 2023.","FDA removed partial clinical hold on zorevunersen; plans to provide Phase 3 data and regulatory update by year-end.","Phase 1 study of STK-002 (ADOA) delayed to focus on zorevunersen."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":13941000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208736,"accession_number":"0001193125-24-216632","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Stoke Therapeutics settles shareholder derivative lawsuit; $590K in fees, governance reforms","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Mootness fee of $175,000 paid to resolve certain director compensation claims; company denies wrongdoing.","Proposed settlement filed Aug 20, 2024; includes corporate governance reforms and up to $415,000 in attorney fees.","Reforms cap director compensation at 65th percentile of peer group and require value-based equity grants and annual consultant review.","Court approval required; settlement hearing scheduled for Oct 28, 2024.","Company agrees to maintain reforms for five years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208735,"accession_number":"0000950170-24-092268","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stoke Therapeutics Q2 net loss $25.7M; FDA lifts partial clinical hold on zorevunersen","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA removed Partial Clinical Hold on zorevunersen for Dravet syndrome; planning Phase 3 registrational study.","Q2 revenue $4.8M (vs. -$2.5M prior year); net loss $25.7M ($0.46/shr) vs. $30.7M ($0.69/shr) prior year.","Cash, cash equivalents, and marketable securities totaled $282M as of June 30, 2024.","On track to initiate Phase 1 OSPREY study of STK-002 for Autosomal Dominant Optic Atrophy in 2024.","Regulatory discussions ongoing; update on Phase 3 registrational plans for zorevunersen expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":9048000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226469,"accession_number":"0001193125-24-165651","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Stoke Therapeutics COO steps down; Huw Nash remains as Chief Business Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Huw Nash, Ph.D., stepped down as COO effective June 18, 2024, by mutual agreement with the company.","Nash continues in his role as Chief Business Officer, retaining business development responsibilities.","No successor Chief Operating Officer was named; the COO position appears eliminated or duties reassigned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226468,"accession_number":"0001193125-24-156049","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stoke Therapeutics shareholders elect three Class II directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Jennifer C. Burstein, Arthur A. Levin, Ph.D., and Ian F. Smith as Class II directors for three-year terms.","Burstein received 32,396,633 votes for; Levin 25,556,568 for; Smith 33,961,032 for; broker non-votes 5,561,508 each.","Ratified KPMG as independent auditor for fiscal 2024 with 39,911,634 votes for, 6,826 against, 9,898 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226467,"accession_number":"0000950170-24-053195","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stoke Therapeutics Q1 net loss $26.4M; STK-001 data supports disease modification","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.4M ($0.57/share) vs $22.5M ($0.53) YoY; cash $178.6M at March 31, plus $120.3M net from April follow-on offering.","STK-001 data from 81 patients showed durable seizure reductions and cognitive/behavior improvements; plans to discuss registrational study with regulators, update H2 2024.","Revenue from Acadia collaboration $4.2M (down from $5.2M); R&D expenses rose to $22.4M from $19.6M.","Appointed Jason Hoitt as CCO and Tommy Leggett as CFO.","Plans to initiate Phase 1 OSPREY trial for STK-002 in ADOA in 2024; FALCON natural history data presented at ARVO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":4216000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226466,"accession_number":"0001193125-24-122215","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Stoke Therapeutics names Thomas Leggett CFO; Stephen Tulipano resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Leggett appointed CFO effective May 7, 2024; previously CFO at Affinia Therapeutics and Black Diamond Therapeutics.","Leggett receives $475,000 base salary, 40% bonus target, and option for 396,200 shares vesting over 4 years.","Current CFO Stephen Tulipano resigns effective May 7; will serve as advisor through Dec 31, 2024.","Tulipano retains equity vesting during transition period and up to $15,000 in outplacement services.","Leggett holds B.A. from Columbia and M.B.A. from Wharton; also board member at Clover Biopharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245474,"accession_number":"0001193125-24-080874","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Stoke Therapeutics prices $125M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 5,555,557 shares at $13.50/share and pre-funded warrants for 3,703,730 shares at $13.4999.","Expected gross proceeds of $125M; net proceeds ~$119.8M after underwriting discounts and expenses.","Net proceeds to fund research, clinical development of STK-001 and STK-002, and other corporate purposes.","Offering expected to close on April 2, 2024; J.P. Morgan acting as sole book-running manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245473,"accession_number":"0001193125-24-076478","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Stoke reports STK-001 data: 85% median seizure reduction at 3 months; FDA allows 70mg dosing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/2a: 70mg (2-3 doses) showed median 85% reduction in convulsive seizure frequency at 3 months (n=10) and 74% at 6 months (n=9) after last dose.","OLE studies: durable seizure reductions and clinically meaningful improvements in cognition/behavior (VINELAND-3) over 12 months with continued 30mg or 45mg dosing.","FDA clearance for three 70mg doses followed by 45mg; company plans to meet with regulators to discuss registrational study design.","STK-001 generally well-tolerated; 30% (24/81) had treatment-related TEAEs, most commonly CSF protein elevation and procedural vomiting.","92% of eligible patients enrolled in OLEs with 84% remaining; data contrast with natural history showing no improvement in seizures or cognition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245472,"accession_number":"0000950170-24-035908","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stoke Therapeutics reports 2023 net loss $104.7M; cash $201.4M to fund to end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & marketable securities $201.4M as of Dec 31, 2023; expected to fund operations through end of 2025.","Net loss for FY 2023 was $104.7M ($2.38 per share) vs $101.1M ($2.60 per share) in 2022.","Revenue from Acadia collaboration fell to $8.8M from $12.4M YoY.","R&D expenses $82.2M (2022: $77.8M); G&A $41.3M (2022: $38.9M), driven by STK-001 and STK-002 development.","Q4 2023 net loss $27.0M ($0.60 per share) vs $25.7M ($0.65 per share) in Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245471,"accession_number":"0001193125-24-003939","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Stoke Therapeutics details 2024 clinical milestones; STK-001 data in Q1, STK-002 trial in UK","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In Q1 2024, plans to report safety, PK, and CSF results from 81 patients in STK-001 Phase 1/2a and OLE studies.","Seizure frequency data from ~20 patients who received 1-3 doses of 70mg STK-001, followed for six months, will be released in Q1.","Repeat dose effects (30mg, 45mg) on seizure frequency and cognition/behavior from OLE studies also expected in Q1.","Depending on Q1 results, plans to start Phase 3 preparation including regulatory discussions and toxicology data.","Phase 1 study of STK-002 for Autosomal Dominant Optic Atrophy expected to begin in UK in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262955,"accession_number":"0001193125-23-295456","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Stoke Therapeutics extends headquarters lease to Dec 2026; aggregate rent ~$5.05M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered first amendment to lease for corporate HQ and lab at 45-47 Wiggins Ave, Bedford, MA.","Lease term extended by two years to December 31, 2026.","Aggregate estimated base rent over extension period approximately $5.05 million.","Option to further extend for five years at 95% of then-prevailing market rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262954,"accession_number":"0001193125-23-286862","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Stoke presents STK-001 data at AES 2023: seizure reductions and cognition gains in Dravet syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Higher STK-001 brain exposure linked to greater seizure reductions in 72 patients (R=-0.23, P<0.001).","Multiple 70mg doses of STK-001 showed the largest reductions in convulsive seizure frequency.","90% of Phase 1/2a completers enrolled in open-label extension studies (SWALLOWTAIL & LONGWING).","BUTTERFLY natural history study: patients on ~3.5 anti-seizure drugs saw no meaningful seizure improvement over 2 years.","OLE data showed substantial improvements in cognition and behavior over 12 months, supporting disease modification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262953,"accession_number":"0000950170-23-059756","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stoke Therapeutics Q3 2023 net loss $24.5M; cash $214.7M funds into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.5M ($0.55 per share) vs $26.1M ($0.66) in Q3 2022.","Revenue of $3.3M from Acadia license/services; cash runway to end of 2025.","STK-001 Phase 1/2a results plus OLE data expected Q1 2024; then regulatory meeting for Phase 3 design.","STK-002 Phase 1 study (OSPREY) for ADOA to start in UK early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":5978000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262952,"accession_number":"0001193125-23-264160","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stoke Therapeutics shareholders approve option exchange for RSUs at special meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted 23,393,135 For, 8,352,191 Against, 26,577 Abstained on proposal.","Approved one-time value-neutral exchange of outstanding employee stock options for restricted stock units.","Exchange applies to options under 2014 and 2019 Equity Incentive Plans held by eligible employees.","Proposal was described as approximately value neutral for shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280150,"accession_number":"0001193125-23-238627","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Stoke Therapeutics appoints Ian Smith to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian Smith appointed as Class II director effective September 19, 2023.","He will receive an annual cash retainer of $40,000 and an initial stock option for 96,340 shares (~$305k fair value).","Smith brings over 20 years experience; served as EVP/COO/CFO at Vertex Pharmaceuticals.","He currently serves on boards of Solid Biosciences (SLDB), Foghorn Therapeutics (FHTX), and others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280149,"accession_number":"0000950170-23-038733","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stoke Therapeutics Q2 2023 net loss $30.7M; cash $231.4M to fund operations to end of 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.7M ($0.69 per share) vs $24.7M ($0.63) in Q2 2022; R&D expenses $20.6M.","Cash and marketable securities $231.4M as of June 30, 2023; expected runway to end of 2025.","Revenue reversed $(2.5)M vs $3.2M a year ago due to $5.3M cumulative catch-up on Acadia collaboration.","STK-001: additional data from MONARCH/ADMIRAL and OLEs expected Q1 2024 to inform Phase 3 design.","STK-002: UK MHRA authorized Phase 1 OSPREY study for ADOA; enrollment in FALCON natural history completed (n=48)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":2671000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280148,"accession_number":"0001193125-23-192735","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STK-001 70mg achieves 80% median convulsive seizure reduction at 3 months in Dravet syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["70mg multiple-dose cohort (n=6): median convulsive seizure reduction 80% at 3 months, 89% at 6 months after last dose.","30mg and 45mg OLE data show durable seizure reductions and improvements in cognition/behavior per VABS-III and BRIEF-P.","Safety: generally well-tolerated in 74 patients; one SUSAR attributed to drug; no treatment-related discontinuations.","Additional Phase 1/2a end-of-study data and Phase 3 planning update expected in Q1 2024 and H1 2024 respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298668,"accession_number":"0001193125-23-170114","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stoke Therapeutics stockholders elect three Class I directors, ratify KPMG, approve charter amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Adrian R. Krainer (23.7M for, 8.0M withheld), Garry E. Menzel (26.0M for, 5.7M withheld), Julie Anne Smith (30.3M for, 1.3M withheld) as Class I directors.","Ratified KPMG as independent auditor for FY 2023 with 35.5M for, 15.9K against, 987 abstentions.","Approved amendment to Certificate of Incorporation: 27.0M for, 4.6M against, 4.7K abstentions.","Broker non-votes of 3.8M shares recorded for director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298667,"accession_number":"0000950170-23-017454","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stoke Therapeutics Q1 2023 net loss $0.53/sh; cash $254.2M; mid-2023 STK-001 data expected","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $0.53, revenue $5.2M from collaboration (up from $3.0M YoY).","Cash, equivalents and securities $254.2M, expected to fund operations to end of 2025.","On track to report Phase 1/2a STK-001 data mid-2023: safety & seizure frequency for up to 16 patients on 45mg.","UK MHRA authorized CTA for STK-002 Phase 1/2 study in ADOA; start expected early 2024.","Company plans to initiate a Phase 3 program in 2024, pending additional Phase 1/2a data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":5152000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318860,"accession_number":"0001193125-23-070652","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA allows Stoke to administer higher 70mg single dose of STK-001 in Dravet syndrome study","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA permits 70mg single dose cohort in Phase 1/2a MONARCH study; dosing expected in coming weeks.","MONARCH remains on partial clinical hold for multiple doses above 45mg; ADMIRAL study continues multiple 70mg dosing.","Data from multiple 45mg doses anticipated mid-2023; data from 70mg (single/multiple) expected H2 2023.","Company on track to complete Phase 1/2a studies in 2023 and initiate Phase 3 program in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318859,"accession_number":"0001564590-23-003162","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stoke Therapeutics reports FY2022 net loss $101.1M; STK-001 shows 55% median seizure reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2022 was $101.1M ($2.60/share) vs $85.8M ($2.34/share) in 2021; revenue of $12.4M from license agreement.","STK-001 interim analysis: 55% median reduction in convulsive seizure frequency in 6 patients after multiple 45mg doses.","Cash, equivalents, and marketable securities $230.2M at Dec 31, 2022; plus $44.7M raised since, extending runway to end of 2025.","Data from multiple 45mg doses expected mid-2023; 70mg dose data in H2 2023; Phase 3 program planned for 2024.","R&D expenses rose to $77.8M (FY2022) from $54.2M (FY2021) driven by STK-001 and STK-002 development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318858,"accession_number":"0001193125-23-024123","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Stoke Therapeutics amends bylaws to conform to DGCL and universal proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Updated provisions on adjournment, stockholder lists, and electronic transmission of notices to align with recent DGCL amendments.","Revised advance notice bylaws require additional disclosures, limit nominees to board seats up for election, and mandate nominee interviews.","Added rules to comply with universal proxy (Rule 14a-19): stockholders must certify compliance and provide evidence 5 business days before meeting.","Requires stockholders soliciting proxies to use a non-white proxy card; authorizes emergency bylaws for quorum issues.","Effective February 2, 2023; no financial or operational impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318857,"accession_number":"0001193125-23-004192","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Stoke updates STK-001 Dravet data timelines: 45mg mid-2023, 70mg H2 2023; STK-002 ADOA Phase 1/2 start 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Multiple-dose STK-001 45mg data expected mid-2023; 70mg data expected second half 2023.","Phase 1/2a for Dravet syndrome to complete in 2023, enabling Phase 3 program in 2024.","STK-002 for ADOA: UK CTA submission expected H1 2023; Phase 1/2 start planned for 2024.","Updated corporate presentation posted ahead of J.P. Morgan Healthcare Conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337093,"accession_number":"0001193125-22-297163","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2022-12-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Stoke Therapeutics reports 55% reduction in convulsive seizures in Phase 1/2a study of STK-001 in Dravet syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["55% median reduction in convulsive seizure frequency from baseline in 6 patients treated with three doses of 45mg STK-001.","5/6 (83%) patients showed reductions; 4/6 (67%) had >50% reduction from baseline.","STK-001 up to 45mg well-tolerated; 27% (15/55) of patients had treatment-related AEs, all mild/moderate, no withdrawals.","Reductions in seizure frequency maintained in SWALLOWTAIL open-label extension; trend toward improvement in executive function (BRIEF-P).","One-year BUTTERFLY observational data showed little change in cognition without STK-001 treatment, highlighting disease progression."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337092,"accession_number":"0001564590-22-037486","cik":1623526,"company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Stoke reports positive interim Phase 1/2a data for STK-001 in Dravet syndrome; 55% median seizure reduction at 45mg","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["STK-001 up to 45mg well-tolerated; 55% median reduction in convulsive seizures with three doses of 45mg (n=6).","74% of patients (20/27) experienced reduction in seizure frequency after three doses of STK-001.","Cash of $252.2M as of Sep 30, 2022 expected to fund operations into 2025; Q3 net loss $26.1M ($0.66/share).","FDA granted Rare Pediatric Disease Designation for STK-001 in Dravet syndrome in October 2022.","Planned data updates on multiple doses of 45mg and 70mg in 2023; AES presentation Dec 2-6."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1943810479.592051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-14T23:59:59+00:00|337092"}